Announcements
- Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
As of last trade Verrica Pharmaceuticals Inc (1NE:FRA) traded at 6.82, -21.85% below its 52-week high of 8.72, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.82 |
---|---|
High | 6.82 |
Low | 6.82 |
Bid | 6.81 |
Offer | 7.09 |
Previous close | 6.84 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.42m |
Free float | 20.49m |
P/E (TTM) | -- |
Market cap | 318.15m USD |
EPS (TTM) | -1.75 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 07:04 BST.
More ▼